MedPath

Peanut Protein Supplementation to Prevent Muscle Atrophy and Improve Recovery Following Total Knee Arthroplasty

Not Applicable
Terminated
Conditions
Surgery
Interventions
Other: Standard Care by Surgeon and Physical Therapist
Dietary Supplement: Peanut Protein Powder
Registration Number
NCT04294563
Lead Sponsor
Auburn University
Brief Summary

This randomized controlled trial will study the effects of peanut protein supplementation on changes in muscle size and quality in patients undergoing total knee arthroplasty.

Detailed Description

Total knee arthroplasty (TKA) is an effective treatment for patients with knee osteoarthritis (OA) accompanied by severe pain and functional limitations. With the success of this treatment and increasing incidence of OA, it has been projected that \~3.5 million older adults will undergo TKA annually by the year 2030. While TKA is effective for reducing pain and improving health-related quality of life, TKA patients experience significant skeletal muscle atrophy and weakness in the surgical leg following surgery which, long-term, can compromise balance, functional mobility and increase fall risk. Thus, interventions to mitigate muscle atrophy and weakness post-surgery are essential to improving long-term outcomes in patients undergoing TKA.

This randomized controlled trial will study the effects of peanut protein supplementation on changes in muscle size and quality in patients undergoing total knee arthroplasty. Patients (n=30) between the ages of 60-75 years scheduled to undergo total knee arthroplasty at the Jack Hughston clinic/hospital will be recruited to participate. Participants will be stratified by gender and randomized to a peanut protein (PP) supplementation (72g daily, n=15) or waitlist control (standard care with no PP, n=15) group who will be provided with PP following the intervention. Participants in the PP group will consume PP daily starting 7 days prior to surgery and for 6 weeks post-surgery. Participants will be monitored for changes in muscle size and quality (peripheral quantitative computed tomography), upper-leg strength (isokinetic dynamometry), knee range of motion (ROM; goniometry), pain (questionnaire and pressure algometry), and functional mobility outcomes (questionnaire, timed up and go, 2-min walk test) prior to surgery and at 6 and 12-weeks post-surgery.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
1
Inclusion Criteria
  • total knee arthroplasty scheduled within two weeks under the care of surgeons at the Jack Hughston Clinic
Exclusion Criteria
  • history of invasive lower extremity surgery within the last 5 years
  • allergy to peanuts or peanut products
  • Body Mass Index <20 or >35 kg/m2
  • currently adhering to a restrictive weight loss diet
  • current or recent (within the last 2 months) steroid use
  • any physical condition that interferes with performing post-surgery rehabilitation
  • known peripheral vascular disease, kidney disease, liver disease, or uncontrolled endocrine disorder
  • known overt cardiovascular or metabolic such as heart disease/failure or diabetes
  • Radiation exposure within the last 6 months other than dental x-rays or associated with current knee treatment/diagnosis

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Wait-llist Control GroupStandard Care by Surgeon and Physical TherapistParticipants will complete baseline measures 7 days prior to total knee arthroplasty and will receive a 7 week supply after completion of 12 week post-surgery visit.
Immediate Intervention GroupStandard Care by Surgeon and Physical TherapistParticipants will complete baseline measures and begin daily supplementation of peanut protein powder (72g/day) 7 days prior to total knee arthroplasty until 6 weeks after surgery.
Immediate Intervention GroupPeanut Protein PowderParticipants will complete baseline measures and begin daily supplementation of peanut protein powder (72g/day) 7 days prior to total knee arthroplasty until 6 weeks after surgery.
Primary Outcome Measures
NameTimeMethod
Change in mid-thigh skeletal muscle area0-6 weeks, 6-12 weeks

peripheral quantitative computed tomography (pQCT) cross-sectional image of mid-right thigh assessed for total muscle cross-sectional area

Change in mid-thigh skeletal muscle area and quality0-6 weeks, 6-12 weeks

peripheral quantitative computed tomography (pQCT) cross-sectional image of mid-right thigh assessed for overall muscle density

Secondary Outcome Measures
NameTimeMethod
Change in leg extensor isokinetic dynamometry0-6 weeks, 6-12 weeks

maximal isokinetic right leg extensions on an isokinetic dynamometer (BioDex)

Physical Function testing0-6 weeks, 6-12 weeks

3 meter up and go test

Change in inflammatory biomarkers0-6 weeks, 6-12 weeks

serum C-reactive protein, interleukin-6, tumor necrosis factor-alpha, plasma 8-hydroxy-2'deoxyguanosine

Physical Performance testing0-6 weeks, 6-12 weeks

2 minute walk test

Oxford Knee Score0-6 weeks, 6-12 weeks

12 question inventory

Trial Locations

Locations (1)

Auburn University

🇺🇸

Auburn, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath